These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

838 related articles for article (PubMed ID: 28438410)

  • 1. Vaccination with recombinant Modified Vaccinia Ankara (MVA) viruses expressing single African horse sickness virus VP2 antigens induced cross-reactive virus neutralising antibodies (VNAb) in horses when administered in combination.
    Manning NM; Bachanek-Bankowska K; Mertens PPC; Castillo-Olivares J
    Vaccine; 2017 Oct; 35(44):6024-6029. PubMed ID: 28438410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The immunogenicity of recombinant vaccines based on modified Vaccinia Ankara (MVA) viruses expressing African horse sickness virus VP2 antigens depends on the levels of expressed VP2 protein delivered to the host.
    Calvo-Pinilla E; Gubbins S; Mertens P; Ortego J; Castillo-Olivares J
    Antiviral Res; 2018 Jun; 154():132-139. PubMed ID: 29678552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A single dose of African horse sickness virus (AHSV) VP2 based vaccines provides complete clinical protection in a mouse model.
    Aksular M; Calvo-Pinilla E; Marín-López A; Ortego J; Chambers AC; King LA; Castillo-Olivares J
    Vaccine; 2018 Nov; 36(46):7003-7010. PubMed ID: 30309744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. VP2 Exchange and NS3/NS3a Deletion in African Horse Sickness Virus (AHSV) in Development of Disabled Infectious Single Animal Vaccine Candidates for AHSV.
    van de Water SG; van Gennip RG; Potgieter CA; Wright IM; van Rijn PA
    J Virol; 2015 Sep; 89(17):8764-72. PubMed ID: 26063433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccination of mice with a modified Vaccinia Ankara (MVA) virus expressing the African horse sickness virus (AHSV) capsid protein VP2 induces virus neutralising antibodies that confer protection against AHSV upon passive immunisation.
    Calvo-Pinilla E; de la Poza F; Gubbins S; Mertens PP; Ortego J; Castillo-Olivares J
    Virus Res; 2014 Feb; 180():23-30. PubMed ID: 24333835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiserum from mice vaccinated with modified vaccinia Ankara virus expressing African horse sickness virus (AHSV) VP2 provides protection when it is administered 48h before, or 48h after challenge.
    Calvo-Pinilla E; de la Poza F; Gubbins S; Mertens PP; Ortego J; Castillo-Olivares J
    Antiviral Res; 2015 Apr; 116():27-33. PubMed ID: 25643968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccination of horses with a recombinant modified vaccinia Ankara virus (MVA) expressing African horse sickness (AHS) virus major capsid protein VP2 provides complete clinical protection against challenge.
    Alberca B; Bachanek-Bankowska K; Cabana M; Calvo-Pinilla E; Viaplana E; Frost L; Gubbins S; Urniza A; Mertens P; Castillo-Olivares J
    Vaccine; 2014 Jun; 32(29):3670-4. PubMed ID: 24837765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of antibody responses to African horse sickness virus (AHSV) in ponies after vaccination with recombinant modified vaccinia Ankara (MVA).
    Chiam R; Sharp E; Maan S; Rao S; Mertens P; Blacklaws B; Davis-Poynter N; Wood J; Castillo-Olivares J
    PLoS One; 2009 Jun; 4(6):e5997. PubMed ID: 19543394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. African horse sickness virus (AHSV) with a deletion of 77 amino acids in NS3/NS3a protein is not virulent and a safe promising AHS Disabled Infectious Single Animal (DISA) vaccine platform.
    van Rijn PA; Maris-Veldhuis MA; Potgieter CA; van Gennip RGP
    Vaccine; 2018 Apr; 36(15):1925-1933. PubMed ID: 29525278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protective immunization of horses with a recombinant canarypox virus vectored vaccine co-expressing genes encoding the outer capsid proteins of African horse sickness virus.
    Guthrie AJ; Quan M; Lourens CW; Audonnet JC; Minke JM; Yao J; He L; Nordgren R; Gardner IA; Maclachlan NJ
    Vaccine; 2009 Jul; 27(33):4434-8. PubMed ID: 19490959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cross-protective immune responses against African horse sickness virus after vaccination with protein NS1 delivered by avian reovirus muNS microspheres and modified vaccinia virus Ankara.
    Marín-López A; Barreiro-Piñeiro N; Utrilla-Trigo S; Barriales D; Benavente J; Nogales A; Martínez-Costas J; Ortego J; Calvo-Pinilla E
    Vaccine; 2020 Jan; 38(4):882-889. PubMed ID: 31708178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serological response of foals to polyvalent and monovalent live-attenuated African horse sickness virus vaccines.
    Crafford JE; Lourens CW; Smit TK; Gardner IA; MacLachlan NJ; Guthrie AJ
    Vaccine; 2014 Jun; 32(29):3611-6. PubMed ID: 24814557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A modified vaccinia Ankara virus (MVA) vaccine expressing African horse sickness virus (AHSV) VP2 protects against AHSV challenge in an IFNAR -/- mouse model.
    Castillo-Olivares J; Calvo-Pinilla E; Casanova I; Bachanek-Bankowska K; Chiam R; Maan S; Nieto JM; Ortego J; Mertens PP
    PLoS One; 2011 Jan; 6(1):e16503. PubMed ID: 21298069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Passive transfer and rate of decay of maternal antibody against African horse sickness virus in South African Thoroughbred foals.
    Crafford JE; Lourens CW; Gardner IA; Maclachlan NJ; Guthrie AJ
    Equine Vet J; 2013 Sep; 45(5):604-7. PubMed ID: 23294121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ns1 is a key protein in the vaccine composition to protect Ifnar(-/-) mice against infection with multiple serotypes of African horse sickness virus.
    de la Poza F; Calvo-Pinilla E; López-Gil E; Marín-López A; Mateos F; Castillo-Olivares J; Lorenzo G; Ortego J
    PLoS One; 2013; 8(7):e70197. PubMed ID: 23894615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant baculovirus-synthesized African horsesickness virus (AHSV) outer-capsid protein VP2 provides protection against virulent AHSV challenge.
    Roy P; Bishop DH; Howard S; Aitchison H; Erasmus B
    J Gen Virol; 1996 Sep; 77 ( Pt 9)():2053-7. PubMed ID: 8811002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assembly of Replication-Incompetent African Horse Sickness Virus Particles: Rational Design of Vaccines for All Serotypes.
    Lulla V; Lulla A; Wernike K; Aebischer A; Beer M; Roy P
    J Virol; 2016 Aug; 90(16):7405-7414. PubMed ID: 27279609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic DIVA tests accompanying the Disabled Infectious Single Animal (DISA) vaccine platform for African horse sickness.
    van Rijn PA; Maris-Veldhuis MA; Boonstra J; van Gennip RGP
    Vaccine; 2018 Jun; 36(25):3584-3592. PubMed ID: 29759377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plant-produced chimeric virus-like particles - a new generation vaccine against African horse sickness.
    Rutkowska DA; Mokoena NB; Tsekoa TL; Dibakwane VS; O'Kennedy MM
    BMC Vet Res; 2019 Dec; 15(1):432. PubMed ID: 31796116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of inactivated African horse sickness (AHS) vaccine formulated with different adjuvants.
    van Rijn PA; Maris-Veldhuis MA; Grobler M; Wright IM; Erasmus BJ; Maartens LH; Potgieter CA
    Vaccine; 2020 Oct; 38(45):7108-7117. PubMed ID: 32921506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.